Monopar Therapeutics (NASDAQ:MNPR) Shares Down 5.7% – What’s Next?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price fell 5.7% during mid-day trading on Monday. The company traded as low as $64.95 and last traded at $66.28. 218,899 shares traded hands during trading, an increase of 57% from the average session volume of 139,654 shares. The stock had previously closed at $70.32.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. UBS Group set a $125.00 price target on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Barclays reissued an “overweight” rating and set a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Morgan Stanley restated an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research note on Monday, August 17th. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, HC Wainwright upped their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Monopar Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $122.00.

Monopar Therapeutics Stock Up 4.2%

The firm has a market capitalization of $488.56 million, a P/E ratio of -33.55 and a beta of 1.62. The business’s 50 day moving average is $88.66 and its 200-day moving average is $77.40.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. Research analysts forecast that Monopar Therapeutics Inc. will post -2.98 EPS for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other news, Director Kim Tsuchimoto sold 2,891 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total transaction of $206,012.66. Following the completion of the transaction, the director directly owned 1,199 shares in the company, valued at approximately $85,440.74. This represents a 70.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $68.35, for a total value of $214,755.70. Following the completion of the transaction, the director directly owned 5,373 shares of the company’s stock, valued at approximately $367,244.55. The trade was a 36.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 51,920 shares of company stock worth $4,527,913. Corporate insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of large investors have recently bought and sold shares of MNPR. Your Advocates Ltd. LLP acquired a new position in Monopar Therapeutics during the 1st quarter worth approximately $183,000. The Manufacturers Life Insurance Company bought a new position in shares of Monopar Therapeutics in the 1st quarter worth $250,000. Sei Investments Co. lifted its holdings in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares in the last quarter. Bank of America Corp DE grew its position in Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares during the period. Finally, Walleye Capital LLC acquired a new stake in Monopar Therapeutics in the 1st quarter valued at $3,458,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.